Pulse Oximetry- Performance During Severe Signal Interference
1 other identifier
observational
17
1 country
1
Brief Summary
Determine accuracy specifications and labeling claims of a pulse oximeter in a diverse subject population during severe signal interference over a specified saturation range.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Aug 2012
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2012
CompletedFirst Submitted
Initial submission to the registry
October 31, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2012
CompletedFirst Posted
Study publicly available on registry
November 2, 2012
CompletedFebruary 13, 2013
February 1, 2013
3 months
October 31, 2012
February 12, 2013
Conditions
Outcome Measures
Primary Outcomes (1)
SpO2 Accuracy (percentage of blood oxygen saturation)
1.5 hours per subject
Eligibility Criteria
Healthy, well perfused
You may qualify if:
- Male or female subjects between the ages of 18 to 50 years (inclusive).
- Must undergo a physical examination by a licensed physician, advanced practice nurse or physician assistant, including a 12 lead ECG, a medical history, and a blood test checking complete blood count and screening for sickle cell trait or disease
- All female volunteers must have a negative urine pregnancy test prior to participation.
You may not qualify if:
- A room-air baseline % modulation \< 1.5% on all four fingers on the test hand
- Pregnancy or lactating women
- History of syncopal episodes
- Hypertension (defined as a systolic pressure of \>145 mmHg or a diastolic pressure \>90 mm Hg on three consecutive readings)
- Premature ventricular contractions (PVC's) that are symptomatic or occur at a rate of more than 5/minute
- History of seizures (except childhood febrile seizures) or epilepsy
- Routine use of tranquilizers and/or excessive anxiety
- History of frequent headaches or migraines
- History of stroke
- Previous injury or trauma to fingers or hands that may change blood flow or vascular supply and affect our ability to test multiple sensors
- History of "altitude sickness" defined as headaches, malaise or dizziness when in the mountains or in an aircraft at altitude significantly above sea level for a prolonged period of time (\> 1 hour)
- History of significant respiratory disease, such as severe asthma, emphysema, etc.
- Sickle cell disease or trait.
- The use of medications, pre-existing medical conditions, treatment for a medical condition or any other reason deemed relevant by the clinician conducting the study.
- A clinically significant abnormal finding on medical history, physical examination, clinical laboratory test or ECG. Clinical significance will be assessed by the principal investigator or designee.
- +8 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Medtronic - MITGlead
Study Sites (1)
Covidien
Boulder, Colorado, 80301, United States
Study Design
- Study Type
- observational
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 31, 2012
First Posted
November 2, 2012
Study Start
August 1, 2012
Primary Completion
November 1, 2012
Study Completion
November 1, 2012
Last Updated
February 13, 2013
Record last verified: 2013-02